- AU$5.34m
- AU$5.18m
- AU$0.41m
Annual income statement for Inhalerx, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.022 | 0.182 | 0.052 | 1.21 | 0.405 |
| Cost of Revenue | |||||
| Gross Profit | -0.147 | 0.067 | 0.052 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.23 | 1.29 | 1.98 | 2.64 | 1.68 |
| Operating Profit | -1.21 | -1.11 | -1.93 | -1.44 | -1.28 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.21 | -1.11 | -1.93 | -1.44 | -1.21 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.21 | -1.11 | -1.93 | -1.44 | -1.21 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.21 | -1.11 | -1.93 | -1.44 | -1.21 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.21 | -1.11 | -1.93 | -1.44 | -1.21 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.012 | -0.007 | -0.011 | -0.008 | -0.006 |